{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:39:45Z","timestamp":1792773585828,"version":"4.5.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001006","name":"The Breast Cancer Research Foundation Inc","doi-asserted-by":"publisher","award":["BCRF-21-133"],"award-info":[{"award-number":["BCRF-21-133"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.esmoop.2026.108352","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T17:56:46Z","timestamp":1786730206000},"page":"108352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Time-dependent prognostic impact of tumor grade in stage I-III breast cancers"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7444-8578","authenticated-orcid":false,"given":"M.","family":"Mariani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ochocki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6790-6267","authenticated-orcid":false,"given":"G.","family":"Bianchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2508-5736","authenticated-orcid":false,"given":"M.","family":"Marczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9632-6686","authenticated-orcid":false,"given":"L.","family":"Pusztai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.esmoop.2026.108352_bib1","first-page":"524","article-title":"Breast cancer statistics, 2022","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"17","key":"10.1016\/j.esmoop.2026.108352_bib2","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJMoa050518","article-title":"Effect of screening and adjuvant therapy on mortality from breast cancer","volume":"353","author":"Berry","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108352_bib3","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108352_bib4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.annonc.2025.10.005","article-title":"Overall survival with abemaciclib in early breast cancer","volume":"37","author":"Johnston","year":"2025","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108352_bib5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMoa2406070","article-title":"Survival with trastuzumab emtansine in residual HER2-positive breast cancer","volume":"392","author":"Geyer","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108352_bib6","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/jnci\/djae241","article-title":"Trends in breast cancer-specific death by clinical stage at diagnoses between 2000 and 2017","volume":"117","author":"Marczyk","year":"2025","journal-title":"J Natl Cancer Inst"},{"issue":"19","key":"10.1016\/j.esmoop.2026.108352_bib7","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108352_bib8","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/jamaoncol.2017.5524","article-title":"Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial","volume":"4","author":"Sestak","year":"2018","journal-title":"JAMA Oncol"},{"issue":"16","key":"10.1016\/j.esmoop.2026.108352_bib9","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1200\/JCO.22.00069","article-title":"Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update","volume":"40","author":"Andre","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108352_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063510","article-title":"The difference in prognostic factors between early recurrence and late recurrence in estrogen receptor-positive breast cancer: nodal stage differently impacts early and late recurrence","volume":"8","author":"Ahn","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108352_bib11","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3481","article-title":"Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers","volume":"15","author":"Bianchini","year":"2013","journal-title":"Breast Cancer Res"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108352_bib12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","article-title":"Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up","volume":"19","author":"Elston","year":"1991","journal-title":"Histopathology"},{"issue":"19","key":"10.1016\/j.esmoop.2026.108352_bib13","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2017.76.4258","article-title":"Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor-positive breast cancer treated with 5 years of endocrine therapy: CTS5","volume":"36","author":"Dowsett","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108352_bib14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108352_bib15","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.2015.64.3809","article-title":"American Cancer Society\/American Society of Clinical Oncology breast cancer survivorship care guideline","volume":"34","author":"Runowicz","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108352_bib16","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.breast.2016.10.005","article-title":"Improved survival in metastatic breast cancer 1985-2016","volume":"31","author":"Sundquist","year":"2017","journal-title":"Breast"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T15:39:41Z","timestamp":1792769981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926022945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2059702926022945"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108352","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time-dependent prognostic impact of tumor grade in stage I-III breast cancers","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108352","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108352"}}